In this webinar, animal models of pain to explore the efficacy of novel new drug candidates will be summarized to include acute, inflammatory and chronic pain conditions.
Animal models of pain to explore the efficacy of novel new drug candidates will be summarized to include acute, inflammatory and chronic pain conditions. Animal models provide pivotal systems for the preclinical study of pain. The Eurofins Panlabs portfolio of several models of chronic pain will be presented; nerve injury, chemotherapy induced models, as well as bone cancer and osteoarthritis induced pain models. Given animals models rely typically on evoked withdrawal responses to noxious stimuli (hyperalgesia) or normally non-noxious stimuli (allodynia); whether it be thermally or mechanically presented, the predictability of these models to translate to the clinical chronic pain condition is often questioned. Furthermore, animal pain models do not simulate multidimensional clinical pain conditions.
Chronic pain, especially neuropathic pain and cancer pain, is often not adequately treated by analgesics now on the market so the need for new therapeutics persists. Patients with neuropathic pain have identifiable ongoing pain produced by inflammation and involvement of central mechanisms. These patients often suffer from spontaneous pain. Recent advances in modeling spontaneous pain will be presented and selected rodent models of non-evoked ongoing pain will be described.
A review of animal models of spontaneous pain will be presented and recent advances in non-evoked ongoing pain in selected rodent models will be described.
Linda Hedley, Global CNS Technical Director, Eurofins Panlabs
Linda Hedley is the former Research Manager CNS Division of Roche Palo Alto LLC, where she spent eighteen years in the neuroscience research field. She has thirty years of experience in pre-clinical pharmacology and drug development with Syntex and Roche combined. Linda has expertise in several therapeutic areas such as, Pain: acute, chronic, and neuropathic, epilepsy, psychosis, anxiety, depression, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and Multiple Sclerosis. Linda has over 24 peer reviewed journal articles and 20 published abstracts. Linda led key drug discovery programs at Roche and worked closely with Primary Investigators to prepare Investigation Brochures and assist in IND preparation. She is a member of the Society of Neuroscience, American Pain Society and served as Council Member and Secretary of the Western Pharmacology Society. She represented Roche as a keynote speaker at the American Association for Laboratory Animal Science and was a member of the Institutional Animal Care and Use Committee for over 10 years. In her current role, she interfaces with Business Development and Operations to conduct efficacy studies for Pharma and Biotech clients worldwide and consults with clients to implement customized study designs for assessing the efficacy of novel compounds in CNS in vivo models.Message Presenter
Tamara King, Ph.D., Assistant Professor, College of Osteopathic Medicine and Center for Excellence in the Neurosciences, University of New England
Tamara King has over 10 years of experience in pain research. Her laboratory uses recently developed approaches that allow for mechanistic evaluation of affective/motivational aspects of pain and pain relief in the preclinical setting. Collaborative efforts with Dr. Frank Porreca at the University of Arizona have developed a novel measure of pain that does not rely on a response evoked by an experimenter, referred to as ongoing or spontaneous pain. These measures have been successfully performed across a variety of preclinical pain models including post-operative pain, neuropathic pain, osteoarthritis pain, and cancer-induced bone pain. Continued efforts in Dr. King’s laboratory at the University of New England are centered on: 1) the role of ascending and descending pathways in chronic pain states; 2) mechanistic differences between ongoing and evoked pain states; and 3) the discovery of molecules that can effectively ameliorate ongoing pain across various preclinical models of pain. The goal of these studies is to contribute to the discovery of alternative approaches to pain management that can be advanced to humans for treatment of chronic pain.
1. Wang, R, King, T, Defelice, M, Guo, W, Ossipov, M, Porreca, F. Descending Facilitation maintains long-term spontaneous neuropathic pain. Journal of Pain. 2013; epub.
2. Navratilova E, Xie JY, King T, Porreca F. Evaluation of reward from pain relief. Annals of the New York Academy of Sciences 2013;1282(1):1-11.
3. King T, Qu C, Okun A, Melemedjian OK, Mandell EK, Maskaykina IY, Navratilova E, Dussor GO, Ghosh S, Price TJ, Porreca F. Contribution of PKMζ-dependent and independent amplification to components of experimental neuropathic pain. Pain. 2012 Jun;153(6):1263-73.
4. Okun A, Liu P, Davis P, Ren J, Remeniuk B, Brion T, Ossipov MH, Xie J, Dussor GO, King T, Porreca F. 2012 Afferent drive elicits ongoing pain in a model of advanced osteoarthritis. Pain, 153, 924-933
5. Navratilova, E., Xie, JY, Okun, A, Eyde, N, Ossipov, M, King, T, Porreca, F. Pain relief is rewarding: pivotal role of the reward pathways in mediating the conditioned place preference by peripheral nerve block in rat incisional pain model. PNAS, 109, 20709-13
6. Okun, A., Defelice M, Eyde N, Ren J, Mercado R, King T, Porreca F. 2011 Transient inflammation-induced ongoing pain is driven by TRPV1 sensitive afferents. Mol Pain, 7: 4.
7. Liu, P., Okun A, Ren J, Rui C, Ossipov MH, Xie J, King T, Porreca F. 2011. Ongoing Pain in the MIA Model of Osteoarthritis. Neurosci Letters 493: 72-75.
8. Qu C, King T, Okun A, Lai J, Fields HL, Porreca F. 2011. Lesion of the rostral anterior cingulate cortex eliminates the aversiveness of spontaneous neuropathic pain following partial or complete axotomy. Pain. 152: 1641-1648.
9. King T, Qu C, Okun A, Mercado R, Ren J, Brion T, Lai J, Porreca F. 2011. Contribution of afferent pathways to nerve injury-induced spontaneous pain and evoked hypersensitivity. Pain. 152: 1997-2005
Who Should Attend?
Individuals with a CNS/Pain Preclinical Pharmacology focus:
- VPs of R&D
- VPs of Translational Medicine
- Directors, Lab Managers, Principal Scientists and Scientists
Eurofins Panlabs is a global CRO specializing in discovery pharmacology testing services. We’ve been in continuous operation for over 40 years serving the Pharmaceutical and biotechnology community, setting the benchmarks for quality, convenience, and scientific expertise.
Our mission is to provide pharmacological testing services that predict clinical effects. Eurofins Panlabs’ scientific portfolio consists of over 1350 tests ranging from molecular assays, to cell-based models, through proof of concept in vivo activity determinations.
We are an extension of our client’s capabilities, providing unrivaled pharmacological expertise and knowledge, superior data reliability, and innovative solutions for drug discovery.